Please select the option that best describes you:
Topics:
Pulmonology • Pulmonary Vascular Disease
How do you approach a patient with recurrent VTE who develops VTE again after reduction of apixaban to 2.5 mg bid?
Would you consider increasing the dose to the usual 5 mg BID or consider it a DOAC failure and switch to coumadin?
Answer from: at Community Practice
Several factors play into this decision for me.
Is the patient obese? Obese patients tend to give me pause for dose-reduction of DOACs. As such, half-dose apixaban may have been relatively underdosed for an obese patient and I would not call it DOAC failure, rather I would increase the dose to us...
Sign In or Register to read more